JP2016104790A5 - - Google Patents

Download PDF

Info

Publication number
JP2016104790A5
JP2016104790A5 JP2016006778A JP2016006778A JP2016104790A5 JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5 JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016006778 A JP2016006778 A JP 2016006778A JP 2016104790 A5 JP2016104790 A5 JP 2016104790A5
Authority
JP
Japan
Prior art keywords
protein
vector
tissue
dna encoding
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2016006778A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016104790A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2016104790A publication Critical patent/JP2016104790A/ja
Publication of JP2016104790A5 publication Critical patent/JP2016104790A5/ja
Ceased legal-status Critical Current

Links

JP2016006778A 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬 Ceased JP2016104790A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2008119324 2008-04-30
JP2008119324 2008-04-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2014019961A Division JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Publications (2)

Publication Number Publication Date
JP2016104790A JP2016104790A (ja) 2016-06-09
JP2016104790A5 true JP2016104790A5 (show.php) 2016-07-21

Family

ID=41255155

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬
JP2016006778A Ceased JP2016104790A (ja) 2008-04-30 2016-01-18 損傷組織の機能的再生促進医薬

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2010510169A Expired - Fee Related JP5814549B2 (ja) 2008-04-30 2009-04-30 損傷組織の機能的再生促進医薬
JP2014019961A Active JP5960735B2 (ja) 2008-04-30 2014-02-05 損傷組織の機能的再生促進医薬

Country Status (10)

Country Link
US (1) US20110097309A1 (show.php)
EP (1) EP2301560A4 (show.php)
JP (3) JP5814549B2 (show.php)
KR (1) KR20110027665A (show.php)
CN (1) CN102076351A (show.php)
AU (1) AU2009240885A1 (show.php)
BR (1) BRPI0911436A2 (show.php)
CA (1) CA2722906A1 (show.php)
RU (1) RU2010148785A (show.php)
WO (1) WO2009133940A1 (show.php)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009133943A1 (ja) 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
JP5660889B2 (ja) * 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬
KR20110027665A (ko) * 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약
RU2016135937A (ru) * 2009-10-28 2018-12-11 Дженомикс Ко., Лтд. Средства для стимуляции регенерации тканей путем привлечения мезинхимных стволовых клеток и/или плюрипотентных стволовых клеток костного мозга в кровь
JP5852773B2 (ja) * 2010-06-01 2016-02-03 ピアス株式会社 骨髄間葉系幹細胞の誘引剤の製造方法、骨髄間葉系幹細胞の誘引方法、及び、骨髄間葉系幹細胞の誘引剤を製造するための使用
WO2012147470A1 (ja) 2011-04-26 2012-11-01 株式会社ジェノミックス 組織再生を誘導するためのペプチドとその利用
BR112015009037A2 (pt) 2012-10-25 2017-11-14 Genomix Co Ltd composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1
PL2913059T3 (pl) 2012-10-25 2018-09-28 Genomix Co., Ltd. Nowy sposób leczenia urazu rdzenia kręgowego z zastosowaniem fragmentu HMGB1
HK1250649A1 (zh) * 2015-09-14 2019-01-11 UNIVERSITé LAVAL 用於治疗白血病的抗-s100a8
CA3051825A1 (en) 2017-01-27 2018-08-02 StemRIM Inc. Therapeutic agent for cardiomyopathy, old myocardial infarction and chronic heart failure
WO2018199107A1 (ja) 2017-04-25 2018-11-01 塩野義製薬株式会社 組織再生を誘導するためのペプチドとその利用
EP3656850A4 (en) * 2017-07-18 2021-03-31 Shiseido Co., Ltd. MESENCHYMATIC STEM CELL INDUCTION AGENT
JPWO2019107530A1 (ja) 2017-12-01 2020-11-26 株式会社ステムリム 炎症性腸疾患の治療薬
CN118460462A (zh) 2017-12-01 2024-08-09 斯特姆里姆有限公司 外胚层间充质干细胞及其产生方法
WO2019156137A1 (ja) 2018-02-08 2019-08-15 株式会社ステムリム 乾癬の治療薬
US12304933B2 (en) * 2018-10-05 2025-05-20 StemRIM Inc. Disease treatment drug based on mesenchymal-stem-cell mobilization
EP3756679A1 (en) * 2019-06-28 2020-12-30 Université de Genève Compositions for use in the treatment of insulin deficiency conditions
CN111494423B (zh) * 2020-04-22 2022-01-25 上海市东方医院(同济大学附属东方医院) 一种干细胞组合物及其应用和干细胞滴液
CN115058388A (zh) * 2022-03-14 2022-09-16 福建医科大学附属协和医院 间充质干细胞创面修复优势功能亚群及其鉴定和应用
CN120837666B (zh) * 2025-09-22 2026-02-10 中国人民解放军军事科学院军事医学研究院 靶向巨噬细胞s100a9蛋白在肝纤维化治疗中的应用

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5658894A (en) * 1989-04-23 1997-08-19 The Trustees Of The University Of Pennsylvania Compositions for inhibiting restenosis
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤
EP1114862A3 (de) * 1999-11-17 2003-08-06 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
ATE373078T1 (de) * 2000-02-24 2007-09-15 Xcyte Therapies Inc Gleichzeitige stimulation und konzentration von zellen
DE10121254A1 (de) * 2001-04-30 2002-11-07 Switch Biotech Ag MRP8/MRP14 Heterodimers oder seiner Einzelkomponenten alleine oder in Kombination zur Behandlung und/oder Prävention von Hauterkrankungen, Wunden und/oder Wundheilungsstörungen, die durch eine verringerte Menge an MRP8/MRP14 Heterodimeren gekennzeichnet sind
AU2002304710A1 (en) * 2001-04-30 2002-11-11 Switch Biotech Ag Mrp8/mrp14 heterodimer, or its individual components in combination, for treating and/or preventing skin diseases, wounds and/or wound-healing disturbances
CN1518604A (zh) * 2001-05-09 2004-08-04 克利夫兰大学医院 用新型基因标记、与之相关的方法和组合物来评测皮肤的紫外辐射损伤
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
KR100704158B1 (ko) * 2001-11-19 2007-04-05 교와 핫꼬 고교 가부시끼가이샤 다분화능 줄기세포를 조직으로부터 말초혈로 동원하는약제
AU2003228099A1 (en) * 2002-07-03 2004-01-23 Centro Cardiologico Monzino S.P.A.-Irccs Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair
WO2004004770A1 (en) * 2002-07-05 2004-01-15 Universite Laval Chemotactic factor inhibitor for modulating inflammatory reactions
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
JP2006517537A (ja) * 2003-01-03 2006-07-27 アルケド バイオテック ゲーエムベーハー Dna結合タンパク質の使用
WO2004075855A2 (en) * 2003-02-26 2004-09-10 Biomed Solutions, Llc Process for in vivo treatment of specific biological targets in bodily fluid
CA2520515C (en) * 2003-03-28 2012-08-28 Universite Laval S100 protein as neutrophil activator for alleviating neutropenia in cancer treatment
AU2005264185A1 (en) * 2004-07-20 2006-01-26 Centro Cardiologico Monzino S.P.A. - Irccs Use of HMGB1 for wound healing
KR100593397B1 (ko) * 2004-10-27 2006-06-28 한국원자력연구소 중배엽 줄기세포 및/또는 p 물질을 함유하는 상처 치유또는 상처 치유 촉진제, 또는 세포 치료제
WO2006047820A1 (en) * 2004-11-01 2006-05-11 Newsouth Innovations Pty Limited Use of calgranulin a and b in the promotion and inhibition of mineralized tissue formation
ES2629086T3 (es) * 2006-10-30 2017-08-07 Genomix Co., Ltd. Sustancia farmacéutica para promover la regeneración funcional de tejido dañado
WO2009133943A1 (ja) * 2008-04-30 2009-11-05 株式会社ジェノミックス 生体内機能的細胞の高効率採取法
KR20110027665A (ko) * 2008-04-30 2011-03-16 가부시키가이샤 제노믹스 손상조직의 기능적 재생 촉진 의약
JP5660889B2 (ja) * 2008-04-30 2015-01-28 株式会社ジェノミックス 末梢循環への骨髄由来多能性幹細胞動員薬

Similar Documents

Publication Publication Date Title
JP2016104790A5 (show.php)
PH12017502424A1 (en) Modified factor ix, and compositions, methods and uses for gene transfer to cells, organs and tissues
WO2018191502A3 (en) Anti-cd137 antibodies and methods of use thereof
PH12018502400A1 (en) Anti-tim-3 antibodies and methods of use thereof
EP4289484A3 (en) Anti-ctla-4 antibodies and methods of use thereof
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
EA201992609A1 (ru) Слитые белки, содержащие интерлейкин-2, и их применения
JP2016514956A5 (show.php)
BR112016029318A2 (pt) tratamento de mielomas
WO2016046778A3 (en) Protease-activatable bispecific proteins
EA201692361A1 (ru) Лентивирусные векторы
WO2015197598A3 (en) Multispecific antigen binding proteins
EA201891317A2 (ru) Терапевтические мишени для коррекции гена дистрофина человека с помощью редактирования генов и способы их применения
WO2016207273A3 (en) Multispecific antigen binding proteins
CY1115502T1 (el) Παραγοντες διεγερσης αποπτωσης για τη θεραπεια καρκινου και ανοσων και αυτοανοσων ασθενειων
JOP20220079A1 (ar) بروتين ربط متعددة الخصوصية لمعالجة السرطان
MX2019013587A (es) Proteinas agonistas del receptor del ligando que induce la apoptosis relacionada con el factor de necrosis de tumor de cadena individual.
UA117045C2 (uk) Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування
CY1125513T1 (el) Προερχομενα απο λιπωδη ιστο στρωματικα αρχεγονα κυτταρα για χρηση σε αγωγη δυσαγωγων περιπλοκων περιπρωκτικων συριγγιων σε νοσο toy crohn
MX2018015629A (es) Sistema de vector viral adeno-asociado traslapado doble para la expresion de abc4a.
RU2016108808A (ru) Терапевтическое применение vegf-c и ccbe1
SG10201805646WA (en) Angiopoietin-like 4 antibodies and methods of use
PH12020550483A1 (en) Anti-apoc3 antibodies and methods of use thereof
EA202091567A1 (ru) Химерные белки мти
WO2016020882A3 (en) Angiopoetin-like 4 (angptl4) antibodies and methods of use